Gilead, Kymera Therapeutics in $750m pact to make new cancer drug
HQ Team June 25, 2025: Gilead Sciences Inc. and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer.
Drugs
Health
Pharma